Background: Previous studies have indicated an association between obesity and poor survival in several tumour types, including ovarian cancer. We sought to test the hypothesis that obesity reduces survival in a large, well-characterised and relatively homogeneous cohort of ovarian cancer patients.
introduction
The incidence of obesity is increasing in the developed world. Obesity is associated with an increased risk of malignancy, contributing to 14%-20% of cancer-related mortality [1] but an association between obesity and cancer survival is less clear. Although obese women are more likely to develop endometrial cancer, there is evidence that they have improved survival [2] and, in ovarian cancer, one study identifying increased body mass index (BMI) as an independent negative prognostic factor for disease-free survival (DFS) and overall survival (OS) [3] and a second study reported an association between BMI > 25 kg/m 2 and reduced survival [4] . These studies are, however, relatively small and nonhomogeneous. We have retrospectively investigated the association between BMI and progression-free survival (PFS) and OS in women with ovarian cancer or peritoneal cancer treated on the Scottish Randomised Trial in Ovarian Cancer (SCOTROC) I study. This trial is a large, multicentre, international, phase III randomised trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy which recruited 1077 patients, therefore allowing analysis of a large number of well-characterised patients treated according to the same protocol. In addition to survival, a pre-planned analysis of BMI and tumour stage/ grade, carboplatin and taxane dose intensity and extent of debulking surgery was carried out.
patients and methods
The SCOTROC I trial is a randomised phase III study, coordinated by the Scottish Gynaecological Cancer Trials Group, to compare efficacy, tolerability and quality of life of docetaxel (TaxotereÒ, Sanofi-Aventis, Guildford, UK)-carboplatin with paclitaxel (TaxolÒ Bristol-Myres Squibb, Uxbridge, UK)-carboplatin as initial chemotherapy for stages Ic-IV ovarian or peritoneal carcinoma.
patients
In all, 1077 patients from 83 international centres were recruited from October 1998 to May 2000. Patients gave written informed consent to participate and the trial had full multicentre ethics committee approval. Separate approval was granted for the analysis of BMI. Patients received docetaxel-carboplatin (n = 537) or paclitaxel-carboplatin (n = 538) (two patients were not treated). Chemotherapy doses were docetaxel 75 mg/m 2 1-h infusion or paclitaxel 175 mg/m 2 3-h infusion, followed by carboplatin area under the curve (AUC) 5 1-h infusion, to a maximum of six cycles. The primary end point of the study was PFS. Trial results have been published [5] .
chemotherapy dose calculation
Carboplatin dose was derived using the Calvert formula [6] . Investigations required before study entry included measurement of glomerular filtration rate (GFR) by plasma clearance of 51 Crethylenediaminotetraacetic acid (EDTA) [7] Tables 1 and 2 . A histogram demonstrating the distribution of BMI in trial patients is shown in Figure 1 .
GFR calculation
GFR was calculated by clearance of 51 Cr-EDTA in 456 patients (42.4%), clearance of 99m Tc-DTPA in 159 patients (14.8%) and 24-h urine collection in 460 patients (42.8%). Information was unavailable for two patients.
PFS and OS
Analysis is restricted to 1067 patients who received taxane treatment and have recorded BMI. Median PFS was 14.7 months [95% confidence interval (CI) 11.6-17.9, n = 59], in the underweight group; 14.7 months (95% CI 13.3-16.1, n = 576), in the ideal weight group; 14.7 months (95% CI 12.6-16.8, n = 303), in the overweight group and 16.6 months (95% CI 11.8-21.4, n = 129), in the obese group. There was no statistically significant association between BMI category and PFS (log-rank test statistic 2.31, P = 0.51, n = 1067).
There was no statistically significant association between BMI category and OS (log-rank test statistic 6.33, P = 0.10, n = 1067), with median OS of 32.9 months (95% CI 23.5-42.4, n = 59), in the underweight group; median not attained in the ideal weight group (n = 576); 30.1 months (95% CI 25.4-34.7, n = 303), in the overweight group and 34.3 months (95% CI Figure 2 .
dose intensity and intended dose
In the SCOTROC I study overall, there were no statistically significant differences between the two arms for dose intensity or cumulative dose [5] . In the current study, there was neither a statistically significant difference in taxane dose intensity between each of the BMI categories (P = 0.120, n = 1067) or carboplatin dose intensity (P = 0.578, n = 1067) nor a statistically significant difference between total intended taxane dose (P = 0.217, n = 1067) or total intended carboplatin dose (P = 0.722, n = 1067). Boxplots of total intended taxane and carboplatin dose are shown in Figure 3 . If there was >10% weight loss when compared with baseline weight during the study, leading to a significant change in BSA, taxane dose was to be reduced accordingly. Overall, 95 patients (0% in the underweight group, 8% in the ideal weight group, 12% in the overweight group and 9% in the obese group) had weight loss of this magnitude during treatment.
association between BMI and tumour stage, grade or debulking surgery
There was no association between BMI and International Federation of Gynecology and Obstetrics tumour stage (P = 0.190, n = 1076), tumour grade (P = 0.280, n = 1076) or extent of debulking surgery (P = 0.194, n = 1076).
discussion
Obesity is associated with poor outcome in several tumour types and a recent study reported an association between high BMI and poor survival in ovarian cancer [3] . The study was, however, relatively small and it may have been confounded by lower dose intensity in obese patients. The SCOTROC I trial offers an opportunity to investigate the impact of BMI on outcome in patients with stages Ic-IV epithelial ovarian or peritoneal cancer, all treated using the same protocol. We do, however, acknowledge that analysis of the relationship between BMI and survival was not one of the original aims of the trial. Table 2 demonstrates no difference between clinico-pathological characteristics in each of the BMI groups, except for a difference between allocated treatment in the underweight group (36% received paclitaxel/carboplatin and 64% received docetaxel/carboplatin). Although the study was designed to investigate the differences between paclitaxel and docetaxel in ovarian cancer management, the study demonstrated no statistically significant difference in PFS or OS between the two groups [5] and the difference in allocated treatment in the underweight group is, therefore, unlikely to be of significance. We found no difference between BMI category and PFS or OS in our study. Furthermore, there was no association between BMI and tumour stage or grade, or completeness of debulking surgery, indicating that these were not confounding factors. Our findings do not support previous reports of original article Annals of Oncology a link between obesity and poorer prognosis in ovarian cancer patients. We indicate that this difference is because of more accurate dose calculations in our study. Carboplatin-paclitaxel is considered standard chemotherapy in ovarian cancer. Carboplatin dose is traditionally calculated using targeted area under the plasma carboplatin concentration-time curve (AUC), rather than using BSA [8] . Using AUC to calculate carboplatin dose correlates with response rates in ovarian cancer [9] . Dose is determined using the Calvert formula, a calculation incorporating the GFR. The most accurate methods of measuring GFR are by analysing plasma clearance of 51 Cr-EDTA [7] or 99m Tc-DTPA following i.v. injection or by 24-h urine creatinine clearance [6, 10] but these approaches are time consuming and expensive. Several formulae have, therefore, been derived which estimate GFR, including the Cockcroft-Gault [11] and Wright [12] formulae.
Several studies have evaluated estimations of GFR and compared them with the gold standard of 51 Cr-EDTA clearance and have concluded that these formulae may underestimate GFR when compared with 51 Cr-EDTA clearance [13, 14] . When analysing the influence of age and BMI on estimates of GFR in obese patients, none of the formulae offered a reliable estimation of GFR [15] and in patients with gynaecological cancer, the accuracy of the calculations became more unreliable at the extremes of BSA [16] . It is possible that, in contrast to SCOTROC I, where the eligibility criteria included calculation of GFR by one of three established and reproducible methods, other studies have used varying methodology, which could have underestimated the carboplatin dose. If this underestimation of dose is particularly marked in the obese population, then this could negatively influence survival data in this group, falsely giving the impression that ovarian cancer patients with a high BMI have a poorer prognosis.
A second reason why obese ovarian cancer patients might appear to have a poorer outcome is because chemotherapy doses in overweight patients are frequently capped in routine practice. The previous study of 216 patients with ovarian or peritoneal cancer which identified increasing BMI as an independent negative prognostic factor for DFS and OS [3] also reported a statistically significant difference in chemotherapy dose between the ideal body weight and obese groups. Although one study in breast cancer suggested that BMI is an independent prognostic factor for OS [18] , others have reported a significantly worse prognosis for patients with higher BMI who were treated on the basis of their ideal body weight [17] , indicating that chemotherapy dosing using ideal body weight may compromise treatment efficacy and adversely affect survival.
Drug elimination may also differ between ideal weight and obese patients. A recent study in patients with solid tumours receiving paclitaxel reported that, for every increase in BSA of 0.2 m 2 , there is a 9% increase in drug elimination [19] . This finding further supports the argument that obese patients should receive chemotherapy based on actual body weight. There was no indication of chemotherapy dose capping in the SCOTROC I trial, as there were no statistically different differences in either taxane or carboplatin dose intensity between each of the four BMI categories.
In conclusion, we have found no association between BMI and outcome in patients with ovarian or peritoneal cancer. We recommend both accurate measurement of GFR before commencing combination chemotherapy and also that patients should receive chemotherapy doses based on actual body weight, rather than ideal body weight.
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